Welcome to the Trintellix website, your go-to information resource for vortioxetine. Here, you can learn about the Trintellix efficacy data and tolerability profile, as well as dosing recommendations, and mode of action.
Trintellix (vortioxetine) is indicated for the treatment of major depressive disorder (MDD) in adults.1
37.5 million patients worldwide and counting2
Trintellix is covered by the Ontario Drug Benefit, RAMQ*, Alberta Health, Manitoba Pharmacare, the Saskatchewan Drug Plan, British Columbia Pharmacare (special authorization), the NBPDP†, the NLPDP‡, NIHB§, Veterans Affairs Canada, Correctional Service Canada, Yukon Pharmacare Plan, Nova Scotia, Prince Edward Island and the Northwest Territories health benefits program.3
Need more samples or information about Trintellix?
Kindly complete the form
and we will be happy to respond.
* RAMQ=Official Mark of the Régie de l'assurance maladie du Québec.
† NBPDP=New Brunswick Prescription Drug Program.
‡ NLPDP=Newfoundland and Labrador Prescription Drug Program.
§ NIHB=Non-insured health benefit.
References: 1. Trintellix Product Monograph. Lundbeck Canada Inc. August 4, 2021. 2. Data on file. Lundbeck Canada Inc. February 2022. 3. Data on file. Trintellix Coverage Canada. Lundbeck. December 2021.